WallStreetZenWallStreetZen

NASDAQ: CABA
Cabaletta Bio Inc Stock Forecast, Predictions & Price Target

Analyst price target for CABA

Based on 7 analysts offering 12 month price targets for Cabaletta Bio Inc.
Min Forecast
$22.00+35.55%
Avg Forecast
$32.29+98.93%
Max Forecast
$50.00+208.07%

Should I buy or sell CABA stock?

Based on 7 analysts offering ratings for Cabaletta Bio Inc.
Strong Buy
Strong Buy
6 analysts 85.71%
Buy
1 analysts 14.29%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CABA stock forecasts and price targets.

CABA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-29
lockedlocked$00.00+00.00%2023-11-29
lockedlocked$00.00+00.00%2023-11-15
lockedlocked$00.00+00.00%2023-10-19
lockedlocked$00.00+00.00%2023-09-18Find Out Why
Citigroup
Top 31%
70
Strong BuyInitiates Coverage On$22.00+35.55%2023-09-05
Guggenheim
Top 29%
72
Strong BuyReiterates$34.00+109.49%2023-08-14

1 of 1

Forecast return on equity

Is CABA forecast to generate an efficient return?
Company
N/A
Industry
-0.69%
Market
30.34%

Forecast return on assets

Is CABA forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.29%

CABA revenue forecast

What is CABA's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$194.3M
Avg 2 year Forecast
$329.8M
Avg 3 year Forecast
$1.1B

CABA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CABA$16.23$32.29+98.93%Strong Buy
EXAI$5.58$10.00+79.21%Strong Buy
DYN$11.18$21.00+87.84%Strong Buy
ADPT$4.71$8.00+69.85%Buy
EYPT$19.15$28.80+50.39%Strong Buy

Cabaletta Bio Stock Forecast FAQ

Is Cabaletta Bio Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: CABA) stock is to Strong Buy CABA stock.

Out of 7 analysts, 6 (85.71%) are recommending CABA as a Strong Buy, 1 (14.29%) are recommending CABA as a Buy, 0 (0%) are recommending CABA as a Hold, 0 (0%) are recommending CABA as a Sell, and 0 (0%) are recommending CABA as a Strong Sell.

If you're new to stock investing, here's how to buy Cabaletta Bio stock.

What is CABA's revenue growth forecast for 2027-2029?

(NASDAQ: CABA) Cabaletta Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.

Cabaletta Bio's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast CABA's revenue for 2027 to be $8,325,640,752, with the lowest CABA revenue forecast at $8,325,640,752, and the highest CABA revenue forecast at $8,325,640,752. On average, 2 Wall Street analysts forecast CABA's revenue for 2028 to be $14,133,450,054, with the lowest CABA revenue forecast at $2,286,444,624, and the highest CABA revenue forecast at $25,980,455,484.

In 2029, CABA is forecast to generate $48,199,589,582 in revenue, with the lowest revenue forecast at $48,199,589,582 and the highest revenue forecast at $48,199,589,582.

What is CABA's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: CABA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.29%.

What is CABA's Price Target?

According to 7 Wall Street analysts that have issued a 1 year CABA price target, the average CABA price target is $32.29, with the highest CABA stock price forecast at $50.00 and the lowest CABA stock price forecast at $22.00.

On average, Wall Street analysts predict that Cabaletta Bio's share price could reach $32.29 by Nov 29, 2024. The average Cabaletta Bio stock price prediction forecasts a potential upside of 98.93% from the current CABA share price of $16.23.

What is CABA's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: CABA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.